Immuneering to present pancreatic cancer data on atebimetinib at AACR conference on Sept. 26

Immuneering to present pancreatic cancer data on atebimetinib at AACR conference on Sept. 26

• Immuneering flagged new analyses from its atebimetinib pancreatic cancer program, with results scheduled for presentation at AACR on Sept. 26, 2026.
• The work extends earlier disclosed clinical findings in first-line patients, focusing on treatment effects on body mass and tumor shrinkage.
• The updated assessment links those changes to overall survival, positioning a dual mechanism as a potential differentiator versus standard approaches.
• The presentation centers on atebimetinib combined with modified gemcitabine and nab-paclitaxel in pancreatic ductal adenocarcinoma.